Stable Soluble scFv Antibodies for TNFα Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TNFα-associated disorders, such as rheumatoid arthritis, often involve antibodies that provide temporary relief but can have side effects and are not sustainably effective, with a need for more stable and soluble antibody forms that can be administered locally with minimal side effects.
Innovation Solution
Development of stable and soluble scFv antibodies or Fab fragments with optimized light and heavy chain variable domains, combined with specific linker sequences, which are designed to have enhanced stability, solubility, and specificity for TNFα, allowing for effective and continuous treatment of inflammatory processes with reduced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional antibodies are used for TNFα-associated disorders, then therapeutic effects are achieved, but stability and solubility are insufficient leading to temporary relief only
Solution Approach 1:
The patent segments the conventional antibody structure into smaller functional units, specifically using scFv (single-chain variable fragment) formats. This segmentation creates more stable and soluble antibody derivatives that maintain therapeutic efficacy while improving duration of action. The scFv format consists of variable regions of heavy and light chains connected by a linker, providing both stability and extended therapeutic effect.
Solution Approach 2:
The patent applies parameter changes by optimizing the amino acid sequences of the antibody variable domains and linker regions. Specific mutations and sequence optimizations are introduced to enhance stability and solubility parameters of the antibody molecule, transforming it from a temporary therapeutic agent to one with sustained long-term efficacy.
2Adaptability or versatility
If conventional antibodies are administered systemically, then therapeutic coverage is achieved, but side effects increase
Solution Approach 1:
The patent applies local quality by designing antibody derivatives with optimized local properties - specifically enhanced stability and solubility at the molecular level. This allows the antibody to maintain its therapeutic function while reducing unwanted systemic effects, as the optimized local characteristics prevent aggregation and improve pharmacokinetic properties.
3Duration of action of moving object
If antibody stability is increased through optimization, then therapeutic duration is extended, but immunogenicity may increase
Solution Approach 1:
The patent carefully balances parameter changes in the amino acid sequences to achieve enhanced stability without significantly increasing immunogenicity. The optimizations focus on structural stability and solubility parameters while maintaining sequences that are sufficiently similar to human antibodies, thereby extending therapeutic duration while minimizing immune response.
Data Source
AI summary
The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.